The safety and tolerability profile of Rezdiffra in the trial was consistent with previous studies, showing a low rate of discontinuations due to adverse events. Madrigal plans to present ...

By the end of last year, more than 11,800 patients were on Rezdiffra. In a conference call on Wednesday, Madrigal CEO Bill Sibold called the progress “an incredible accomplishment in just nine ...

The study revealed that Rezdiffra, a selective thyroid hormone receptor-ß agonist, was well-tolerated, with a safety profile consistent with earlier trials. The treatment showed a low rate of ...